This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?
by Kinjel Shah
PFE faces a decline in COVID revenues, LOE pressure and IRA impacts but rising EPS estimates offer a glimmer of resilience.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?
by Kinjel Shah
JNJ stock added $15B in market value in six months as new drug launches offset MedTech and Stelara headwinds.
J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications
by Zacks Equity Research
JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.
Zacks Investment Ideas feature highlights: Jabil, Apple, Amazon, Johnson & Johnson and Ericsson
by Zacks Equity Research
Jabil tops Q3 estimates with 35% EPS growth, strong guidance, and momentum from key clients like Apple and Amazon.
Don't Overlook Jabil (JBL) Stock After Topping Its Q3 Expectations
by Shaun Pruitt
Trading near 52-week highs of over $200 a share, Jabil (JBL) stock may be poised for more upside after posting strong results for its fiscal third quarter this week.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
ISRG's Minimally Invasive Ecosystem Powers Surgical Precision
by Indrajit Bandyopadhyay
ISRG's robotic platforms, led by da Vinci and Ion, are transforming surgical precision and driving strong stock gains.
Should WisdomTree U.S. LargeCap Dividend ETF (DLN) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DLN
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DHS
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the most recent trading session, Johnson & Johnson (JNJ) closed at $155.22, indicating a -1.2% shift from the previous trading day.
Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?
by Kinjel Shah
JNJ's Innovative Medicines unit shows a growth trend, defying Stelara LOE and the negative impact of the Part D redesign.
BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth?
by Sridatri Sarkar
Boston Scientific's Q1 2025 Endoscopy sales jump 6%, powered by innovation in stents, clips and surgical tools for GI care.
Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?
by Kinjel Shah
JNJ edges ahead of MRK with stronger 2025 growth prospects, a broader pipeline and better sales momentum despite key headwinds.
The Zacks Analyst Blog Highlights Johnson & Johnson, T-Mobile, The Boeing and Franklin Financial Services
by Zacks Equity Research
JNJ, TMUS, BA, and FRAF show strong momentum as earnings growth, market share, and strategic moves fuel investor confidence.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Top Analyst Reports for Johnson & Johnson, T-Mobile US & Boeing
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, T-Mobile US, and The Boeing Company.
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
by Sundeep Ganoria
ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.
Is WisdomTree U.S. LargeCap Dividend ETF (DLN) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DLN
Intuitive Surgical Stock Gains 12.7% QTD: Is it Still a Buy Now?
by Indrajit Bandyopadhyay
ISRG's shares seem to recover after declining more than 30% from its all-time high. Is it the right time to invest?
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer
by Zacks Equity Research
Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong phase III data.